Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study.

Save

Introduction

The aim of this work was to evaluate the achievement of minimal clinically important improvement (MCII) in patient-reported outcomes (PROs) with guselkumab among participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi-IR).

Methods

Post hoc analysis of phase 3b COSMOS study of participants with PsA and TNFi-IR randomized to guselkumab (N = 189) or placebo (N = 96) at week (W)0, W4 then every 8W through W44, with W16 (early escape) or W24 placebo-to-guselkumab transition. Time to MCII achievement (> 15-point) in patient global assessment of arthritis (PtGA Arthritis), PtGA Psoriasis, PtGA Arthritis + Psoriasis, and Patient Pain, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue, ≥ 4-point), Health Assessment Questionnaire-Disability Index (HAQ-DI, ≥ 0.35-point), 36-item Short-Form Health Survey physical component summary score (≥ 5-point), Dermatology Life Quality Index (DLQI, ≥ 5-point), and DLQI 0/1 with guselkumab vs. placebo was determined using Cox regression adjusting for baseline factors. Logistic regression compared MCII achievement rates between treatment groups.

All p values are nominal.

Results

Time to MCII achievement across PROs through W24 was significantly faster with guselkumab vs. placebo (hazard ratio [HR] range 1.59 for PtGA Arthritis to 5.89 for DLQI), except for FACIT-Fatigue (HR 1.29, 95% confidence interval 0.93–1.81). Guselkumab treatment delivered significant improvements in PROs vs. placebo as early as W8 and through W24. Across all measures, odds of achieving MCII were higher with guselkumab vs. placebo at W8 (odds ratio [OR] range 1.43 for FACIT-Fatigue to 9.33 for DLQI) and W24 (OR range 3.12 for HAQ-DI to 19.42 for DLQI 0/1).

MCII achievement rates for all PROs increased through W48 of guselkumab treatment, with consistent patterns following placebo-to-guselkumab transition.

Conclusions

In these hypothesis-generating analyses of a TNFi-IR PsA population, guselkumab demonstrated rapid (W8) MCII achievement in patient-reported skin and joint symptoms, and pain, followed by improvements in fatigue, functional status, and quality of life, with response rates increasing further through W48.

Trial Registration

ClinicalTrials.gov identifier, NCT03796858.

Key Summary Points

Why carry out this study?The phase 3 COSMOS study demonstrated that treatment with the interleukin-23p19 inhibitor guselkumab resulted in significantly greater improvements in joint and skin disease compared with placebo through 6 months among participants with active psoriatic arthritis (PsA) with inadequate response to tumor necrosis factor inhibitors (TNFi-IR).Patient-reported outcomes (PROs) are self-reported measures for assessing PsA symptoms, functional status and health-related quality of life (HRQoL) impacted by the disease, thus complementing clinical examination.These post hoc hypothesis-generating analyses of the COSMOS study assessed the impact of guselkumab treatment on changes in various PROs, as well as achievement of minimal clinically important improvement (MCII) in these measures.What was learned from the study?Among participants with PsA and TNFi-IR, greater improvements in patient-reported arthritis, skin psoriasis, overall PsA disease activity, pain, fatigue, physical function and HRQoL were observed with guselkumab compared with placebo as early as at the first timepoint of assessment (week 4 or 8).The time to achieve MCII in the examined PROs was also significantly faster with guselkumab than placebo through 6 months, except for fatigue, and participants receiving guselkumab had greater odds of attaining MCII and improved HRQoL as early as at week 8 and through 1 year.Guselkumab has the potential to benefit patients with treatment-resistant active PsA by providing improvements across symptoms most important to patients.

Introduction

Psoriatic arthritis (PsA) is a chronic, inflammatory disease that can manifest in diverse clinical domains including peripheral arthritis, dactylitis, enthesitis, psoriasis, and psoriatic nail disease [1]. PsA is associated with a significant burden on patient health-related quality of life (HRQoL), including physical and emotional functioning, ability to perform daily activities, and work productivity [2]. Pain, fatigue, and physical function are of high importance to patients with PsA and can be difficult to treat effectively [3].

As majority of patients present with multi-symptom disease, treatment should reduce disease activity across all active PsA domains while optimizing functional status and improving QoL [1].

International treatment guidelines recommend escalating treatment to a biologic disease-modifying antirheumatic drug (bDMARD) upon insufficient response to conventional synthetic (cs) DMARDs, which often include tumor necrosis factor α inhibitors (TNFi) in moderate to severely active PsA [1, 4, 5]. A considerable proportion of patients fail initial TNFi and have lower responses and higher rates of treatment discontinuation or switching to a subsequent TNFi or a different biologic treatment compared with TNFi-naïve patients [6–8]. New therapies that enable patients with inadequate response to TNFi (TNFi-IR) to achieve improvements similar to patients who are bDMARD-naïve are needed.

Patient perspective on the impact of disease is a key component of PsA activity assessment and patient-reported outcome (PRO) instruments provide insight into wider aspects of the condition, encompassing pain, fatigue, physical function, and disease-specific HRQoL, as well as gauge response to treatment [9]. The minimal clinically important improvement (MCII), defined as the smallest improvement in a measurement that a patient would perceive as beneficial [10], has been derived for several PsA outcome measures [11]. As such, MCIIs assist in the interpretation of the effects of interventions by providing a threshold for meaningful improvement relevant to patients and may thus aid shared decision-making.

Furthermore, use of therapies conveying improvements that fail to surpass MCII thresholds may not justify exposing patients to the associated risks.

Guselkumab is a fully human interleukin (IL)-23 inhibitor targeting the IL-23p19-subunit. The phase 3b COSMOS trial (NCT03796858) demonstrated that guselkumab delivers significantly greater improvements vs. placebo in joint and skin disease at week 24 in participants with active PsA with TNFi-IR [12]. The objective of the present analysis was to evaluate the effect of guselkumab on time to and achievement of MCII in PROs through week 48 of COSMOS among TNF-IR participants with active PsA.

Methods

Participants and Study Design

Details of the COSMOS study design, eligibility criteria, and primary results have been previously reported [12]. Briefly, COSMOS was a phase 3b randomized, double-blind, controlled trial of participants with active PsA and TNFi-IR. Eligible participants had ≥ 3 swollen and ≥ 3 tender joints (SJC/TJC) and active or documented history of discontinuing 1–2 TNFi due to lack of efficacy or intolerance.

Participants were randomized (2:1) to guselkumab 100 mg or placebo at week 0, week 4, and then every 8 weeks (Q8W) through week 44. Participants receiving placebo transitioned to guselkumab Q8W at week 16 (early escape if < 5% improvement in SJC/TJC) or week 24.

Ethics

The COSMOS study was conducted in accordance with principles of the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice [13]. Each site’s ethical body approved the study protocol and all participants provided written informed consent.

Patient-Reported Outcomes

A summary of PRO measures used in the present analysis, MCII thresholds and timepoints of first assessment is provided in Table 1. Patient global assessment (PtGA) was used to evaluate the levels of arthritis disease activity (PtGA Arthritis), skin psoriasis (PtGA Psoriasis), and overall PsA disease (PtGA Arthritis + Psoriasis) on a visual analogue scale (VAS) of 0–100 mm. Participants reported their level of pain using the Patient Pain VAS.

Achievement of MCII in PtGA Arthritis, PtGA Psoriasis, PtGA Arthritis + Psoriasis and Patient Pain was based on prior study where a value of 15% (or > 15-point reduction) of a scale range, such as the VAS, was identified as a plausible threshold for noticeable change in a PRO measure [14]. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue; MCII ≥ 4-point reduction) instrument evaluated fatigue symptoms [15]. Physical function was assessed with the Health Assessment Questionnaire-Disability Index (HAQ-DI; MCII ≥ 0.35-unit reduction) [16], and the impact of PsA on physical health was assessed with the 36-item Short-Form Health Survey physical component summary score (SF-36 PCS; MCII ≥ 5-point increase) [17, 18].

Effect of psoriasis and its treatment on HRQoL was evaluated using the Dermatology Life Quality Index (DLQI; MCII ≥ 5-point reduction) [19–21]. MCII in DLQI was measured among participants with DLQI ≥ 5, psoriatic body surface area (BSA) ≥ 3%, and an Investigator’s Global Assessment (IGA) score ≥ 2 at baseline. A DLQI score of 0/1, interpreted as psoriasis having no effect on a patient’s life over the past week [22], was also assessed.

Table 1Summary of PRO measures assessed in COSMOS, first timepoints of assessment, and corresponding MCII thresholds utilized in the present analysisPRO measure (score range)Week of first assessmentMCII thresholdPtGA Arthritis (VAS 0–100)4≥ 15 mm [14]PtGA Psoriasis (VAS 0–100)8≥ 15 mm [14]PtGA Arthritis + Psoriasis (VAS 0–100)4≥ 15 mm [14]Patient Pain (VAS 0–100)4≥ 15 mm [14]FACIT-Fatigue (0–52; lower score = more fatigue)8≥ 4 [15]HAQ-DI (0–3)4≥ 0.35 [16]DLQI (0–30)8≥ 5 [20, 21]DLQI 0/18–SF-36 PCS (US norm = 50; lower score = more impairment)8≥ 5 [18]DLQI Dermatology Life Quality Index, FACIT Functional Assessment of Chronic Illness Therapy, HAQ-DI Health Assessment Questionnaire-Disability Index, MCII minimal clinically important improvement, PRO patient-reported outcome, PtGA patient global assessment, SF-36 PCS 36-item Short-Form Health Survey Physical Component Summary, US United States, VAS visual analog scale

Statistical Analyses

Efficacy analyses through week 24 were performed using the full analysis population that included all randomized participants who received ≥ 1 dose (complete or partial) of the study agent. Efficacy analyses from week 24 through week 48 were performed using all randomized participants who continued study treatment at week 24. For MCII achievement in each PRO measure, analyses were limited to participants with baseline levels above the threshold for the respective outcome score to avoid a floor effect.

Least-squares mean (LSM) changes from baseline in the respective PRO measures were determined using a mixed-effect model for repeated measures adjusted for treatment (guselkumab Q8W, placebo), baseline use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), number of prior TNFi (1 vs. 2), and baseline score of the respective outcome.

Time to achieve each outcome through week 24 was compared between treatment groups using Cox regression, adjusting for baseline outcome levels, prior TNFi use (1 vs. 2), and baseline use of csDMARDs (yes/no). Participants who did not achieve MCII through week 24 were right-censored at the time of last assessment; those not achieving MCII through week 16 that took the early escape route at week 16 were right-censored at week 16.

Rates of MCII achievement for each PRO measure were compared between treatment groups through week 24 with logistic regression, adjusting for baseline outcome levels, prior TNFi use (1 vs. 2), and baseline use of csDMARDs (yes/no). Response rates through week 48 were determined using nonresponder imputation (NRI) for missing data and participants meeting treatment failure criteria.

All p values were nominal and considered hypothesis-generating.

Results

Participant Baseline Characteristics

A total of 285 participants were randomized in COSMOS (guselkumab Q8W: n = 189; placebo: n = 96) [12] and included in this analysis. Baseline demographics, disease characteristics, and medication use were generally similar across treatment arms, except for a numerically higher proportion of female participants in the guselkumab group than in the placebo group (54% vs. 46%; Table 2).

Participants treated with guselkumab also had greater skin involvement vs. placebo (psoriatic BSA of 17.9% vs. 13.4%; Psoriasis Area and Severity Index [PASI] score of 11.7 vs. 9.2; and an IGA score ≥ 2 in 79% vs.

70% of participants). Baseline patient-reported assessments were consistent with physician-derived measures, both indicating active disease across PsA domains and impaired HRQoL (Table 2). Most participants discontinued prior TNFi due to lack of efficacy (84%) [12].

Through week 44, 167 (88%) participants in the guselkumab group and 83 (86%) in the placebo-crossover group completed the study treatment; 4% and 5% of participants discontinued from the study through week 44 in the guselkumab and placebo groups, respectively [12]. Table 2Baseline demographics and disease characteristics of participants with active PsA and TNFi-IR in COSMOSGuselkumab Q8W (N = 189)Placebo (N = 96)Total (N = 285)Demographics Age, years49 (12)49 (12)49 (12) Female103 (54)44 (46)147 (52) BMI, kg/m229 (6)31 (7)a30 (6)bPsA characteristics PsA duration, years8.3 (7.8)8.7 (7.2)8.4 (7.6) SJC (0–68)/TJC (0–68)10 (7)/21 (13)9 (6)/18 (11)10 (6)/20 (12) CRP, mg/dl1.2 (2.0)c1.2 (2.5)1.2 (2.2)b DAPSAd45.5 (19.9)40.6 (15.8)43.8 (18.7) IGA ≥ 2 (mild-severe disease), n (%)149 (79)67 (70)216 (76) Psoriatic BSA, %17.9 (21.5)13.4 (17.7)16.4 (20.4) PASI (0–72)11.7 (11.9)c9.2 (9.4)10.9 (11.2)Patient-reported outcomes PtGA Arthritis (VAS 0–100)65.2 (17.5)62.2 (17. 4)64.2 (17.5) PtGA Psoriasis (VAS 0–100)63.4 (23.5)56.0 (24.0)60.9 (23.90) PtGA Arthritis + Psoriasis (VAS 0–100)67.6 (18.0)64.4 (17.6)66.6 (17.9) Patient Pain (VAS 0–100)64.6 (18.7)60.3 (18.1)63.2 (18.61) FACIT-Fatiguee (0–52)29.2 (11.3)c29.2 (10.6)29.2 (11.0)b HAQ-DIf (0–3)1.3 (0.6)c1.2 (0.6)1.3 (0.6)b DLQIg (0–30)13.5 (6.8)12.4 (7.3)13.1 (7.0) SF-36 PCSh (0–100)33.0 (7.0)c33.9 (7.7)33.3 (7.3)bMedication use, n (%) Number of prior TNFi 1167 (88)85 (89)252 (88) 222 (12)11 (11)33 (12) csDMARDs120 (63)60 (63)180 (63)Data presented are mean (SD) unless otherwise specifiedBMI body mass index, BSA body surface area, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAPSA Disease Activity Index for Psoriatic Arthritis, DLQI Dermatology Life Quality Index, FACIT Functional Assessment of Chronic Illness Therapy, HAQ-DI Health Assessment Questionnaire-Disability Index, IGA Investigator’s Global Assessment, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, PtGA patient global assessment, Q8W every 8 weeks, SD standard deviation, SF-36 PCS 36-item Short-Form Health Survey Physical Component Summary, SJC swollen joint count, TJC tender joint count, TNFi tumor necrosis factor inhibitor, TNFi-IR inadequate response to TNFi, VAS visual analog scaleaN = 95bN = 284cN = 188dDAPSA disease activity states are defined as: remission (≤ 4), low disease activity (4 > to ≤ 14), moderate disease activity (14 > to ≤ 28), and high disease activity (> 28) [35]eHigher scores indicate less fatigue [36].

Previously determined United States general population sample FACIT-Fatigue scores range from 43.5 ± 8.3 to 46.6 ± 7.2 [37–39]fHAQ-DI score of 0–1 indicates mild difficulties to moderate disability, score of 1–2 indicates moderate to severe disability, and score of 2–3 indicates severe to very severe disability [40]gHigher scores indicate greater impairment of skin-specific health-related quality of life [19]. DLQI score of 0–1 indicates no effect on patient’s life, score of 2–5 indicates small effect on patient’s life, score of 6–10 indicates moderate effect on patient’s life, score of 11–20 indicates very large effect on patient’s life, and score of 21–30 indicates extremely large effect on patient’s life [22]hHigher score defines a more favorable health state. SF-36 PCS score has been standardized to a mean of 50, with a score above 50 representing better than average and below 50 poorer than average function [17]

Pattern of PRO Improvement

Participants with guselkumab compared with placebo achieved significant improvements in PtGA Arthritis as of week 12 (LSM change from baseline: − 11.4 vs. − 3.9, respectively, p = 0.0060), and in PtGA Psoriasis (LSM change from baseline: − 22.5 vs. − 7.3, p < 0.0001), and PtGA Arthritis + Psoriasis as of week 8 (LSM change from baseline: − 13.7 vs. − 6.4, p = 0.0037; Fig. 1a–c). Similarly, significant guselkumab efficacy in Patient Pain and FACIT-Fatigue was observed vs. placebo as of week 12 (LSM change from baseline: − 11.2 vs. − 4.9, p = 0.0233) and week 16 (LSM change from baseline: 4.3 vs.

1.7, p = 0.0059), respectively (Fig. 1d, e). Significantly greater improvements were also recorded with guselkumab than placebo in HAQ-DI as of week 12 (LSM change from baseline: − 0.2 vs.

0.0, p = 0.0005), SF-36 PCS starting at week 16 (LSM change from baseline: 3.3 vs. 0.4, p = 0.0002), and DLQI as of week 8 (LSM change from baseline: − 6.3 vs. − 1.5, p < 0.0001; Fig. 1f–h).

Across all measures, improvements with guselkumab were maintained or further enhanced at subsequent visits through week 24 (all p ≤ 0.05).Fig. 1Least-squares mean changes from baseline through week 24 in patient-reported joint disease (A), skin psoriasis (B), overall disease (C), pain (D), fatigue (E), physical function (F) and HRQoL (G, H) among participants with active PsA and TNFi-IR. *p < 0.05, **p < 0.01, ***p < 0.001 for guselkumab vs. placebo; p values are nominal. PtGA BSA body surface area, DLQI Dermatology Life Quality Index, FACIT Functional Assessment of Chronic Illness Therapy, GUS guselkumab, HAQ-DI Health Assessment Questionnaire-Disability Index, IGA Investigator’s Global Assessment, LSM least-squares mean, MCII minimal clinically important improvement, NRI non-responder imputation, ns not significant, PBO placebo, PsA psoriatic arthritis, PtGA patient global assessment, Q8W every 8 weeks, SF-36 PCS 36-item Short-Form Health Survey physical component summary, TNFi-IR inadequate response to tumor necrosis factors inhibitors

Time to Achievement of Clinically Meaningful Improvement Across PROs

Time to achieve MCII in all examined PROs was significantly faster with guselkumab than placebo through week 24, with hazard ratios (95% confidence interval [CI]) ranging from 1.29 (1.15–2.20, p = 0.0050) for PtGA Arthritis to 5.89 (3.13–11.05, p < 0.0001) for DLQI, except for FACIT-Fatigue (Fig. 2). Although the time to achieve MCII in FACIT-Fatigue was faster with guselkumab vs. placebo (HR 1.29), the difference did not reach statistical significance.

Time to achieve DLQI 0/1 was also significantly faster with guselkumab compared with placebo through week 24 (HR 4.92, 1.76–13.72, p < 0.0001).Fig. 2Hazard ratio for time to achievement of MCII in PRO measures and DLQI 0/1 through week 24 with guselkumab vs placebo among participants with active PsA and TNFi-IR. CI confidence interval, DLQI Dermatology Life Quality Index, FACIT Functional Assessment of Chronic Illness Therapy, GUS guselkumab, HAQ-DI Health Assessment Questionnaire-Disability Index, HR hazard ratio, MCII minimal clinically important improvement, PRO patient-reported outcome, PsA psoriatic arthritis, PtGA patient global assessment, Q8W every 8 weeks, SF-36 PCS 36-item Short-Form Health Survey physical component summary, TNFi-IR inadequate response to tumor necrosis factor inhibitors

Achievement of Clinically Meaningful Improvement in PROs

The likelihood of achieving MCII in PtGA Arthritis was significantly higher with guselkumab compared with placebo at week 8 and through week 24 (odds ratio [OR] range 1.85–4.54, all p < 0.05; Fig. 3a). ORs for achieving MCII in PtGA Psoriasis (OR 2.98–10.24, p < 0.01) and PtGA Arthritis + Psoriasis (OR 3.03–5.16, all p < 0.0001) were also significantly higher with guselkumab than placebo at week 8 and through week 24 (Fig.

3b, c). Participants in the guselkumab group had a significantly higher likelihood of achieving MCII in Patient Pain at week 8 and through week 24 (OR range 2.32–3.68, p < 0.01) compared with those in the placebo group (Fig. 3d).

Guselkumab also demonstrated efficacy in achieving MCII in FACIT-Fatigue at week 16 and week 24 vs. placebo (ORs 2.16 and 3.17, respectively, both p < 0.01), although the magnitude of effect appeared lower than for other outcomes (Fig. 3e). Week 16 and week 24 odds of achieving MCII in HAQ-DI (OR 4.52 and 4.04, respectively, p < 0.0001) and SF-36 PCS (OR 3.07 and 4.14, both p < 0.0010) were significantly higher with guselkumab compared with placebo (Fig.

3f, g). Efficacy of guselkumab was also seen in achieving MCII in DLQI at week 8 and through week 24 (OR 9.33–17.88, all p < 0.0001; Fig. 3h).

Similarly, the likelihood of achieving DLQI 0/1 was significantly higher with guselkumab than placebo at week 16 (OR 6.79, p = 0.0113) and week 24 (19.42, p = 0.0043; Fig. 3i). Rates of achievement of clinically meaningful improvements in all examined PRO measures increased further at week 48 with guselkumab, with comparable results seen among participants in the placebo-to-guselkumab transition group.Fig.

3Achievement of MCII (NRI) in patient-reported joint disease (A), skin psoriasis (B), overall disease (C), pain (D), fatigue (E), physical function (F) and HRQoL (G–I) among participants with active PsA and TNFi-IR through week 48. p ≥ 0.05; *p < 0.05; **p ≤ 0.01; ***p ≤ 0.0001 vs. placebo. Odds ratios (95% confidence interval) and nominal p values comparing guselkumab vs. placebo are derived from logistic regression adjusting for baseline patient-reported outcome levels, number of prior TNFi, and concomitant use of conventional synthetic disease-modifying antirheumatic drugs. Results for the placebo to guselkumab crossover group at week 48 are reported for participants without early escape, who crossed over to guselkumab at week 24.

PtGA Psoriasis MCII was assessed in participants with BSA ≥ 3%, and IGA ≥ 2 at baseline. HAQ-DI response was assessed in participants with HAQ-DI ≥ 0.35 at baseline. DLQI MCII was assessed in participants with DLQI score ≥ 5, BSA ≥ 3%, and IGA ≥ 2 at baseline.

DLQI 0/1 was assessed in participants with DLQI score > 1, BSA ≥ 3% and IGA ≥ 2 at baseline. BSA body surface area, DLQI Dermatology Life Quality Index, FACIT Functional Assessment of Chronic Illness Therapy, GUS guselkumab, HAQ-DI Health Assessment Questionnaire-Disability Index, IGA Investigator’s Global Assessment, MCII minimal clinically important improvement, NRI non-responder imputation, ns not significant, PBO placebo, PsA psoriatic arthritis, PtGA patient global assessment, Q8W every 8 weeks, SF-36 PCS 36-item Short-Form Health Survey physical component summary, TNFi-IR inadequate response to TNFi

Discussion

The present analysis demonstrated that participants with PsA and TNFi-IR in the phase 3b COSMOS study with considerable pain, high levels of fatigue, poor functional status and significant impairment in HRQoL at baseline, experienced early and durable improvements in patient-reported arthritis, skin psoriasis, overall PsA disease, pain, fatigue, physical function and HRQoL with guselkumab Q8W. Domain-specific differences, both in effect size and time to achieving improvements, were observed, with patient-reported skin psoriasis and the associated HRQoL being particularly responsive; arthritis, pain and physical function following an intermediate trajectory; and fatigue being more persistent. Specifically, improvements in patient-reported skin psoriasis and skin-specific HRQoL with guselkumab were significantly greater as of the first timepoint of assessment at week 8, and significant improvements were achieved in overall disease, joint symptoms, pain, fatigue, physical function and HRQoL at 8 to 16 weeks of guselkumab treatment.

Improvements in all outcomes with guselkumab were maintained or enhanced through 6 months. Treatment with guselkumab was also associated with a significantly faster time to achievement of MCII in all outcomes through 6 months, except FACIT-Fatigue, as compared with placebo. These findings likely reflect the multifactorial origins of fatigue with both disease-related factors, such as inflammatory burden, pain, and functional impairment, and comorbidities including anxiety, depression, sleep disturbance and fibromyalgia common in PsA, which make it more difficult to treat with a single intervention, requiring a comprehensive approach [23–25].

Achievement of MCII in joint and skin disease, pain and DLQI was significantly higher with guselkumab vs. placebo as early as at week 8 and participants treated with guselkumab had significantly higher odds of achieving MCII in the examined PROs through 6 months compared with placebo. High PRO MCII response rates with guselkumab treatment were durable through 1 year (61.4–74.0%). The robust association between guselkumab treatment and achievement of DLQI 0/1 (no impact of psoriasis on HRQoL) at all examined timepoints is consistent with the established guselkumab efficacy in moderate-to-severe psoriasis, where it has demonstrated long-term disease control [26–29].

The present findings are consistent with those of recent post hoc analyses of data pooled from the DISCOVER studies, demonstrating that in a mixed population of participants with PsA significant proportions of participants treated with guselkumab achieved early (week 4 or 8) MCII in PRO measures, including pain, fatigue, physical function and HRQoL [30]. Notably, rates of fatigue response with guselkumab observed in the present analysis approximated those reported among biologic-naïve participants treated with guselkumab in the DISCOVER-2 study, suggesting that guselkumab may offer the same level of improvement in fatigue regardless of previous TNFi treatment [31].

PROs reflect many important issues that significantly impact patients with PsA. Recent studies have identified joint pain, skin symptoms, fatigue, and physical disability as some of the most prominent PsA symptoms [9, 32], with pain, fatigue, and poor HRQoL ranking highest in priority for treatment among patients [33]. The present findings demonstrate that guselkumab has the potential to provide substantial benefits across symptoms that most affect patients with PsA.

Strengths of the study include low guselkumab discontinuation rates in COSMOS and employment of the conservative NRI approach for missing response rate data, as well as use of validated PRO instruments with defined MCII thresholds. In the absence of PsA-specific MCII cutoffs, thresholds validated in rheumatoid arthritis and psoriasis were selected, as they measure common constructs in disease populations that are clinically comparable to those in the present study. The employed cutoffs are also commonly used in PsA literature.

As MCIIs for PtGA and patient pain have not been established, a 15% improvement (≥ 15 mm) was proposed to represent a sufficiently certain noticeable change as per the Institute for Quality and Efficiency in Health Care (IQWiG) General Methods [14]. Some imbalances were seen between the treatment groups, with a higher proportion of female participants and more severe baseline skin disease in the guselkumab group. Considering that female sex is known to be linked with worse PROs in PsA [34], these imbalances contribute to a more conservative analysis, thus strengthening the conclusions of this study.

The present analysis was limited by the fact that the COSMOS trial was not powered to evaluate assessments included in the present study and results of analyses conducted on a clinical trial population may not be generalizable to the broader population of patients with PsA.

Conclusions

In these hypothesis-generating results in participants with PsA and TNFi treatment-resistant disease, guselkumab associated with early (week 8) and generally faster (compared with placebo) clinically meaningful improvements in patient-reported skin and joint symptoms, pain, fatigue, functional status, and skin-specific and physical function-related HRQoL, with increasing response rates between 6 months and 1 year. Guselkumab may be a promising therapeutic option for improving clinical symptoms and aspects of HRQoL of highest priority to patients, warranting further investigation.

Related articles

PubMed

Does weather matter? Exploring associations between season and meteorological factors and psoriatic arthritis disease activity.

Abstract Objective To investigate the associations between season and psoriatic arthritis (PsA) disease activity, and whether certain meteorological factors are associated with these seasonal differences. Secondary objectives include assessing associations between season and mood. Methods A retrospective longitudinal study was conducted including 935 patients with PsA from the Dutch South West Psoriatic Arthritis cohort from 2013 to 2023. Disease activity was assessed using Psoriatic Arthrit...

PubMed

Adult-onset chronic nonbacterial osteitis mimicking refractory axial psoriatic arthritis: successful treatment with combined IL-1/IL-17 inhibition: a case report and brief literature review.

We report a 46-year-old man with palmoplantar pustular psoriasis and severe axial inflammation who was initially diagnosed with refractory axial psoriatic arthritis. Despite sequential treatment with multiple biologic and targeted therapies, disease activity persisted. Reassessment based on anterior chest wall involvement, characteristic positron emission tomography/computed tomography findings, human leukocyte antigen B27 negativity, and exclusion of infectious, malignant, and monogenic autoinf...